Number of items: 4.
2020
Earl, Helena,
Hiller, Louise,
Vallier, Anne-Laure,
Loi, Shrushma,
McAdam, Karen,
Hughes-Davies, Luke,
Rea, Daniel,
Howe, Donna L.,
Raynes, Kerry,
Higgins, Helen B. et al.
(2020)
Six versus 12 monthsβ adjuvant trastuzumab in patients with HER2-positive early breast cancer : the PERSEPHONE non-inferiority RCT.
Health Technology Assessment, 24
(40).
pp. 1-190.
doi:
10.3310/hta24400
ISSN 1366-5278.
2019
Earl, Helena M.,
Hiller, Louise,
Vallier, Anne-Laure,
Loi, Shrushma,
McAdam, Karen,
Hughes-Davies, Luke,
Harnett, Adrian N,
Ah-See, Mei-Lin,
Simcock, Richard,
Rea, Daniel et al.
(2019)
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE) : 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
The Lancet, 393
(10191).
pp. 2599-2612.
doi:
10.1016/S0140-6736(19)30650-6
ISSN 0140-6736.
2018
Hiller, Louise, Dunn, Janet A., Loi, Shrushma, Vallier, Anne-Laure, Howe, Donna L., Cameron, David A., Miles, David, Wardley, Andrew M. and Earl, Helena M.
(2018)
Adjuvant trastuzumab duration trials in HER2 positive breast cancer : what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.
BMC Cancer, 18
.
391.
doi:10.1186/s12885-018-4307-8
ISSN 1471-2407.
2017
Hiller, Louise, Loi, S., Vallier, A. L., Howe, Donna L., Bell, P., Carey, J., Manazar, Uzma, Cameron, D., Miles, D. and Wardley, A.
(2017)
Measurement methods for eliciting opinions on treatment benefits, toxicities and acceptable trade-offs of the two, within the PERSEPHONE trial.
Trials, 18
(Supplement 1).
p. 200.
P368 [pp139].
ISSN 1745-6215
doi:10.1186/s13063-017-1902-y
This list was generated on Thu Mar 28 23:43:54 2024 GMT.